My understanding is that dementia sufferers are not in any pain or discomfort because they are not really aware of their situation. Dementia sufferers don’t know that they have dementia. If MGC can develop a product that can improve memory or at least slow the dementia process down then they really will have a winner. However I doubt that they will prove anything much in a 16 week trial.
I’m guessing that the next trial will be CanCann for cancer sufferers?
I think that the market is getting rather tired of the research which is essentially endless and waiting for some sustainable revenue flows before committing to an investment.
This is not what I would call a major announcement. Any research facility would be happy to have funding made available to it to for academic interest. It’s more of an announcement for the university rather than MGC.
